Cardiac Function and Cardiovascular Risk Profile in Testicular Cancer Patients

NCT00705094 | Completed

• 1 other identifier: GU-24167
• Study Type: observational
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

For many years, researchers and doctors have studied different kinds of treatments to improve the survival of men with testicular cancer. However, recent research has shown that many years later, men who had testicular cancer appear to be at higher risk for developing heart disease (heart attack or heart failure), especially if they received chemotherapy. Since these studies were done many years after men received treatment, there was no way to know if other factors contributed to the health problems they experienced. This study is being done because it would be helpful to study heart function and cardiovascular disease risk factors of men who have been diagnosed with testicular cancer, before and after they receive chemotherapy treatment compared to men who receive treatment with surgery alone.

Conditions

Testicular Cancer; Seminoma; Non-seminomatous

Keywords

cardiovascular risk factors; cardiac function; VO2peak; Chemotherapy

Study Arms (2)

1

Testicular cancer patients who have received surgery and are scheduled for surveillance

2

Testicular cancer patients who have received surgery and are scheduled for chemotherapy

Eligibility Criteria

• Age: 18 Years+
• Sex: male
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

testicular cancer patients who have recieved surgery and are scheduled for either chemotherapy or surveillance

You may qualify if:

• surgery and surveillance
• surgery and multi-cycle chemotherapy
• both good and intermediate prognosis seminoma and non-seminomatous germ cell testicular tumors
• Karnofsky performance index \> 70%
• no contraindications to cardiopulmonary testing

You may not qualify if:

• documented cardiovascular disease or evidence of myocardial ischemia on the incremental exercise (VO2peak) test.

Sponsors & Collaborators

• AHS Cancer Control Alberta: lead

Study Sites (1)

Cross Cancer Institute

Edmonton, Alberta, T6G 1Z2, Canada

Location

MeSH Terms

Conditions

Testicular Neoplasms; Seminoma

Condition Hierarchy (Ancestors)

Endocrine Gland Neoplasms; Neoplasms by Site; Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Male Urogenital Diseases; Endocrine System Diseases; Testicular Diseases; Gonadal Disorders; Germinoma; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type

Study Officials

• Mark Haykowsky, PhD

  University of Alberta

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 23, 2008
• First Posted: June 25, 2008
• Study Start: September 1, 2008
• Primary Completion: May 1, 2011
• Study Completion: July 1, 2012
• Last Updated: October 1, 2014

Record last verified: 2014-09

Locations

CA (1)